Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) Profit After Tax: 2023-2025

Historic Profit After Tax for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to -$51.5 million.

  • Zenas BioPharma's Profit After Tax fell 33.40% to -$51.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$189.9 million, marking a year-over-year decrease of 47.24%. This contributed to the annual value of -$157.0 million for FY2024, which is 322.91% down from last year.
  • Per Zenas BioPharma's latest filing, its Profit After Tax stood at -$51.5 million for Q3 2025, which was up 1.38% from -$52.2 million recorded in Q2 2025.
  • Zenas BioPharma's Profit After Tax's 5-year high stood at $35.6 million during Q3 2023, with a 5-year trough of -$52.6 million in Q4 2024.
  • Its 3-year average for Profit After Tax is -$31.5 million, with a median of -$38.0 million in 2024.
  • Data for Zenas BioPharma's Profit After Tax shows a maximum YoY plummeted of 208.42% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Zenas BioPharma's Profit After Tax stood at -$24.6 million in 2023, then plummeted by 113.93% to -$52.6 million in 2024, then plummeted by 33.40% to -$51.5 million in 2025.
  • Its Profit After Tax was -$51.5 million in Q3 2025, compared to -$52.2 million in Q2 2025 and -$33.6 million in Q1 2025.